Profile data is unavailable for this security.
About the company
Sihuan Pharmaceutical Holdings Group Ltd is an investment holding company primarily engaged in the research and development, manufacture and sale of pharmaceutical products and aesthetic products. The Company operates its business through three segments. The Medical Aesthetic Products segment includes the filling, shaping, supporting, supplementing, optoelectronic device, body sculpturing, skin care and others to provide non- or minimally invasive medical aesthetic comprehensive solutions. The Innovative Medicine and Other Medicine segment is engaged in the research and development and commercialization of innovative medicine in the disease fields of diabetes, breast cancer, digestion disorders, oncology and non-alcoholic steatohepatitis and others. The Generic Medicine segment is engaged in the production and sale of generic medicine including Kelin’ao and other products. The Company conducts its business in the domestic and overseas markets.
- Revenue in HKD (TTM)2.01bn
- Net income in HKD-58.32m
- Incorporated2006
- Employees2.87k
- LocationSihuan Pharmaceutical Holdings Group Ltd21/F, Building 2,Zhbng 2000 Bsns CtrWest BalizhuangChaoyang DistrictBEIJING 100025ChinaCHN
- Phone+86 75 588609726
- Fax+86 1 052278758
- Websitehttp://www.sihuanpharm.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jiangsu Recbio Technology Co Ltd | 0.00 | -617.47m | 4.34bn | 472.00 | -- | 3.72 | -- | -- | -1.28 | -1.28 | 0.00 | 2.41 | 0.00 | -- | -- | 0.00 | -25.47 | -- | -30.68 | -- | -- | -- | -- | -- | 2.33 | -- | 0.378 | -- | -- | -- | 20.86 | -- | -- | -- |
| Shandong Boan Biotechnology Co Ltd | 667.32m | -128.88m | 4.59bn | 813.00 | -- | 3.22 | -- | 6.88 | -0.2531 | -0.2531 | 1.31 | 2.80 | 0.2732 | 1.35 | 2.53 | 820,806.90 | -5.28 | -- | -7.02 | -- | 66.16 | -- | -19.31 | -- | 0.8383 | -7.47 | 0.2491 | -- | 19.80 | -- | 64.02 | -- | -- | -- |
| Ocumension Therapeutics | 265.97m | -410.01m | 4.68bn | 444.00 | -- | 1.48 | -- | 17.60 | -0.6319 | -0.6319 | 0.4097 | 4.56 | 0.078 | 3.61 | 2.12 | 599,034.80 | -12.03 | -38.78 | -13.21 | -41.47 | 58.60 | 62.30 | -154.16 | -975.82 | 3.72 | -- | 0.0451 | -- | 54.99 | -- | 5.68 | -- | 319.66 | -- |
| Beijing Luzhu Biotechnology Co Ltd | 0.00 | -269.19m | 4.73bn | 133.00 | -- | 4.33 | -- | -- | -1.35 | -1.35 | 0.00 | 5.44 | -- | -- | -- | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | 6.41 | -- | 0.0185 | -- | -- | -- | 65.62 | -- | -- | -- |
| Consun Pharmaceutical Group Ltd | 2.80bn | 846.96m | 4.81bn | 3.13k | 5.38 | 1.18 | 5.16 | 1.72 | 1.06 | 1.06 | 3.50 | 4.83 | 0.4981 | 2.08 | 10.05 | 894,218.40 | 15.13 | 12.04 | 22.57 | 19.25 | 74.19 | 74.55 | 30.37 | 24.89 | 2.62 | -- | 0.1155 | 40.84 | 10.71 | 7.03 | 14.88 | 11.01 | -22.93 | 18.43 |
| Sihuan Pharmaceutical Holdings Group Ltd | 2.01bn | -58.32m | 4.85bn | 2.87k | -- | 1.01 | -- | 2.41 | -0.0063 | -0.0063 | 0.216 | 0.5128 | 0.1572 | 0.8101 | 4.72 | 699,369.60 | -2.18 | -6.85 | -3.34 | -9.10 | 69.64 | 75.81 | -13.85 | -36.23 | 1.35 | -2.63 | 0.1863 | -- | -14.70 | -8.60 | 97.23 | -- | 0.9325 | -- |
| Shanghai Fudan-Zhangjiang Bio-Pharm. Co | 873.63m | 110.32m | 5.46bn | 948.00 | 16.32 | 0.712 | -- | 6.26 | 0.1072 | 0.1072 | 0.8296 | 2.46 | 0.2852 | 1.44 | 1.62 | 921,547.10 | 3.59 | 7.03 | 4.35 | 9.05 | 91.40 | 92.17 | 12.59 | 17.26 | 3.94 | 568.37 | 0.0062 | 39.16 | -17.50 | 2.78 | -21.28 | -0.6326 | 20.49 | -- |
| Everest Medicines Ltd | 135.95m | -911.66m | 6.11bn | 432.00 | -- | 1.12 | -- | 44.92 | -2.92 | -2.92 | 0.4343 | 16.80 | 0.0203 | 2.25 | 4.57 | 314,705.80 | -13.63 | -30.52 | -15.06 | -33.14 | 72.67 | -- | -670.57 | -5,745.25 | 8.29 | -- | 0.0979 | -- | 884.46 | -- | -241.50 | -- | 4.65 | -- |
| China Shineway Pharmaceutical Group Ltd | 4.88bn | 1.05bn | 6.59bn | 3.44k | 5.75 | 0.8679 | 5.38 | 1.35 | 1.39 | 1.39 | 6.45 | 9.18 | 0.5073 | 1.44 | 6.31 | 1,419,074.00 | 10.89 | 8.03 | 14.15 | 9.77 | 75.15 | 74.55 | 21.47 | 17.87 | 2.98 | -- | 0.0411 | 36.29 | 14.32 | 11.94 | 34.14 | 13.89 | 0.6396 | 12.88 |
| Tong Ren Tang Technologies Co Ltd | 7.31bn | 637.15m | 6.63bn | 4.10k | 10.41 | 0.892 | 4.85 | 0.9073 | 0.4975 | 0.4975 | 5.71 | 5.81 | 0.5212 | 0.9835 | 5.68 | 1,783,091.00 | 7.64 | 7.68 | 12.10 | 12.32 | 42.04 | 43.50 | 14.65 | 16.11 | 2.37 | -- | 0.1443 | 39.94 | 13.04 | 6.01 | 1.25 | -2.73 | -22.26 | -0.0089 |
| Beijing Tong Ren Tang Chinese Medicine | 1.52bn | 540.39m | 7.12bn | 798.00 | 13.17 | 1.84 | 10.57 | 4.67 | 0.6456 | 0.6456 | 1.82 | 4.62 | 0.3522 | 0.6449 | 2.31 | 1,910,959.00 | 13.64 | 16.71 | 15.50 | 18.75 | 68.67 | 69.88 | 38.73 | 40.72 | 8.59 | -- | 0.0317 | 68.87 | -11.91 | 0.1459 | -16.33 | -1.43 | -16.30 | 7.49 |
Data as of Jul 26 2024. Currency figures normalised to Sihuan Pharmaceutical Holdings Group Ltd's reporting currency: Hong Kong Dollar HKD
4.49%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Jul 2024 | 150.54m | 1.61% |
| BlackRock Fund Advisorsas of 04 Jul 2024 | 61.27m | 0.66% |
| Dimensional Fund Advisors LPas of 04 Jul 2024 | 58.02m | 0.62% |
| GF Fund Management Co., Ltd.as of 31 Dec 2023 | 56.02m | 0.60% |
| Bosera Asset Management Co., Ltd.as of 31 Dec 2022 | 32.73m | 0.35% |
| China Asset Management Co., Ltd.as of 31 Dec 2023 | 19.07m | 0.20% |
| Penghua Fund Management Co., Ltd.as of 31 Dec 2023 | 15.12m | 0.16% |
| BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 13.95m | 0.15% |
| SSgA Funds Management, Inc.as of 03 Jul 2024 | 6.37m | 0.07% |
| American Century Investment Management, Inc.as of 03 Jul 2024 | 5.93m | 0.06% |
More ▼
Data from 31 Dec 2023 - 24 Jul 2024Source: FactSet Research Systems Inc.
